Benefits to the Company:  Lessen effect on recognition impairment of investment and goodwill into the consolidated financial statements  the burden of Debt to Equity of the consolidated financial

at 31 December 2018 and 2019, the Company’ s debt- to- equity ratios were 0. 89 and 0. 77, respectively. They were at a low level as the Company only had short-term loans which were current liabilities

million, respectively. - Translation - 5 As at 31 December 2019 and 30 June 2020, the Company’s debt-to-equity ratios were 0.77 and 0.78, respectively. They were at a low level as the Company only had short

Company’s working capital as well as current portion of long-term loan from the Company’s investments. If excluding LQSF, current ratio would be 0.78x. Interest-bearing Debt to Equity (Times) As at 30 June

0.07 times of shareholders' equity, as of the consolidated financial statements, as of 30 September 2017. And when total liabilities of consolidated financial statements, as of 30 September 2017, debt to

of 30 September 2017, debt to equity is in the ratio to shareholders' equity in 0.84:1). 9) Opinion of the Company's Board of Directors on the transaction : Approved Board of Directors had assessment

debt to equity ratio 0.35 times, shown that its sufficient liquidity and strong financial position. Please be informed accordingly, Yours Sincerely, DOD Biotech Public Company Limited (Miss Suwarin

Company still had current ratio 1.34 times and debt to equity ratio 0.38 times, shown that its sufficient liquidity and strong financial position. Please be informed accordingly, Yours Sincerely, DOD

ratio (current assets to current liabilities) of the Group was at 9.31 times which increased from the end of the prior year. It was high liquidity. And the debt to equity ratio of the Group was at 0.13

high liquidity. And the debt to equity ratio of the Group was at 0.10 times, the proportion of the liabilities was low.